Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Artelo Biosciences Inc (ARTL)
NASDAQ:ARTL
RESEARCH TOOLSreports
Artelo Biosciences (ARTL) Stock Price & Analysis
443 Followers
ARTL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.15 - $2.98
Previous Close$1.35
Volume3.56K
Average Volume (3M)85.47K
Market Cap
$4.36M
Enterprise Value-$1.93M
Total Cash (Recent Filing)$6.41M
Total Debt (Recent Filing)$127.00K
Price to Earnings (P/E)―
Beta0.28
Next Earnings
Aug 07, 2024EPS Estimate
-$0.79Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.13
Shares Outstanding3,227,700
10 Day Avg. Volume8,821
30 Day Avg. Volume85,472
Standard Deviation0.47
R-Squared0.08
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)0.56
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.20
Forecast
1Y Price Target
$16.67Price Target Upside1134.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Artelo Biosciences News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressArtelo is now poised to advance the company’s Cancer Appetite Recovery Study (CAReS) clinical trial with ART27.13 from Phase 1 into the Phase 2a evaluation of proof-of-concept efficacy.
Debt FinancingJet.AI Inc. secured new debt financing and upsized aircraft orders, which are significant positives.
EarningsLakeland Industries, Inc. results beat on fire and disposables segment growth, prompting raised guidance.
Bears Say
Clinical TrialsInvestment thesis risks include failure of clinical trials to prove efficacy, regulatory requirements for additional clinical studies, and potential need to raise additional funds under poor market conditions.
Dividend CoverageGeneration Income Properties, Inc. likely has no near-term dividend coverage based on lower core FFO estimates.
Net LossArtelo reported a net loss greater than forecast due to higher operating expenses as clinical program activities accelerated.
---
Ownership Overview
20.90%
Insiders
0.72% Mutual Funds
<0.01% Other Institutional Investors
78.37% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ARTL FAQ
What was Artelo Biosciences Inc’s price range in the past 12 months?
Artelo Biosciences Inc lowest stock price was $1.15 and its highest was $2.98 in the past 12 months.
What is Artelo Biosciences Inc’s market cap?
Currently, no data Available
When is Artelo Biosciences Inc’s upcoming earnings report date?
Artelo Biosciences Inc’s upcoming earnings report date is Aug 07, 2024 which is in 10 days.
How were Artelo Biosciences Inc’s earnings last quarter?
Artelo Biosciences Inc released its earnings results on May 09, 2024. The company reported -$0.78 earnings per share for the quarter, beating the consensus estimate of -$0.98 by $0.2.
Is Artelo Biosciences Inc overvalued?
According to Wall Street analysts Artelo Biosciences Inc’s price is currently Undervalued.
Does Artelo Biosciences Inc pay dividends?
Artelo Biosciences Inc does not currently pay dividends.
What is Artelo Biosciences Inc’s EPS estimate?
Artelo Biosciences Inc’s EPS estimate is -$0.79.
How many shares outstanding does Artelo Biosciences Inc have?
Artelo Biosciences Inc has 3,227,700 shares outstanding.
What happened to Artelo Biosciences Inc’s price movement after its last earnings report?
Artelo Biosciences Inc reported an EPS of -$0.78 in its last earnings report, beating expectations of -$0.98. Following the earnings report the stock price went up 4.511%.
Which hedge fund is a major shareholder of Artelo Biosciences Inc?
Currently, no hedge funds are holding shares in ARTL
---
Artelo Biosciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.67 (1134.27% Upside)
$16.67 (1134.27% Upside)
Crowd Wisdom
Positive
Last 7 Days ▼ 1.7%
Last 30 Days ▲ 3.2%
Last 30 Days ▲ 3.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.41%
12-Months-Change
Fundamentals
Return on Equity
-70.68%
Trailing 12-Months
Asset Growth
-43.97%
Trailing 12-Months
Company Description
Artelo Biosciences Inc
Artelo Biosciences, Inc. is a development stage company, which engages in discovering, licensing, developing and commercializing treatments that modulate the endocannabinoid system. The company was founded by James Manley on May 2, 2011 and is headquartered in San Diego, CA.
---
ARTL Stock 12 Month Forecast
Average Price Target
$16.67
▲(1134.27% Upside)
Technical Analysis
Best Analysts Covering ARTL
1 Year
1 Year Success Rate
2/14 ratings generated profit
1 Year Average Return
-36.12%
reiterated a buy rating 2 months ago
Copying Vernon Bernardino's trades and holding each position for 1 Year would result in 14.29% of your transactions generating a profit, with an average return of -36.12% per trade.
---